RS-2026-25502077

Development of Lead Compounds for Pancreatic Cancer Targeting GSPT1 and ZFP91 via a Molecular Glue Based Next-Generation Protein Degradation Strategy

CoBX Bio

CoBX Bio

ONCOLOGY | **Hit**

Product Type	TPD
Indication	PDAC
Target	GSPT1/ZFP91
MoA(Mechanism of Action)	GSPT1/ZFP91 dual molecular glue degrader
Competitiveness	• **Focused indication in pancreatic cancer** Unlike many existing GSPT1 degraders primarily developed for hematologic malignancies or MYC-driven tumors, our program is strategically focused on pancreatic cancer, an area with high unmet medical need and limited therapeutic options. • **First-in-class GSPT1/ZFP91 dual degrader approach** Our compound is designed as a dual degrader targeting both GSPT1 and ZFP91, enabling simultaneous modulation of translational control and oncogenic signaling pathways. This differentiated mechanism may provide enhanced anti-tumor efficacy compared with conventional single-target degraders. • **Biomarker strategy beyond MYC dependency** While many competitors mainly rely on MYC amplification or MYC-driven signatures as biomarkers, we are expanding patient stratification through the identification of additional biomarkers beyond MYC, including neuroendocrine-related factors. This approach may broaden clinical applicability, particularly in neuroendocrine-like tumor subtypes, and improve patient selection strategies. • **Novel positioning within the targeted protein degradation field** Our program represents a differentiated positioning in the TPD landscape by combining solid tumor focus, dual-target degradation, and next-generation biomarker selection.
Development Stage	Hit
Route of Administration	Oral administration